This research study is being done to find out if the study drug, ONTAK (denileukin diftitox), can shrink or slow the growth of B-cell non-Hodgkin’s lymphoma (NHL) in patients whose disease has not responded to prior treatments or has relapsed after an initial response to prior treatments. Patients will be treated with ONTAK for 3 days in a row during the first week, then one-time per week for at least 8 weeks, then depending upon the patient’s response, 8 additional times (once per week). After 16 weeks of treatment, additional monthly doses may be given.

1. Relapsed/refractory B-cell NHL
2. Histological documentation of diffuse large B-cell lymphoma, follicular lymphoma (grade 1, 2 or 3), small lymphocytic lymphoma, or transformed B-cell lymphoma
3. Measurable disease, with at least one lymph node or tumor mass measuring 4 cm2
4. ECOG performance status 0-2
5. Failure to respond or progression of disease after 2 prior treatment regimens
6. Adequate bone marrow, liver, and kidney organ function 

1. Patients must have a confirmed diagnosis of non-Hodgkin’s lymphoma.
2. Patients must meet study for tumor size and staging of the disease.
3. Patients must have adequate organ function and no active uncontrolled infections.
4. Patients must have no prior history of cancer with a few exceptions.
5. Patients may not have had prior chemotherapy, radiotherapy or immunotherapy for lymphoma with the exception of prednisone or other corticosteroids for non-lymphomatous conditions.

1. Patients must have a confirmed diagnosis of aggressive and intermediate grade of Non-Hodgkin’s lymphoma.
2. Patients must have radiologically measurable disease by PET scan.
3. Patients must have adequate staging of the lymphoma.
4. Patients may not have undergone previous chemotherapy including rituximab and steroids, or radiation therapy.
5. Patients must have normal liver and bone marrow function.
6. Patients must have adequate cardiac function.

1. Patients must have prior enrollment in, and documented progression while entered on study FavId-06.
2. Patients who received salvage therapy after completion of study FavId-06, at last 4 weeks and not longer than 4 months, between the completion of salvage treatment and the first dose of FavId on this study.
3. Patents who have not received salvage therapy after completion of study FavId 06, at least 4 weeks, and not longer than 4 months, between completion of enrollment on study FavId-06 and the first dose of FavId on this study.
4. Patients may not have previously received FavId on study FavId-06.

1. Patients must have histologically confirmed follicular B-cell lymphoma.
2. Patients must be candidates for Rituximab as defined by being either treatment naïve, relapsed or refractory following chemotherapy, or relapsed following a prior documented response of at least 6 months duration.
3. Patients may not have received more than 2 prior treatment regimens for NHL.
4. Patients may not have received treatment with fludarabine within 9 months of study entry or receipt of greater than 6 cycles of fludarabine in subject’s lifetime.
5. Patients must have normal bone marrow function.

1. Patients must have histologically or histologically confirmed using the REAL Classification, relapsed /or refractory: chronic lymphocytic leukemia; B-cell small lymphocytic lymphoma; any marginal zone lymphoma; follicle center cell lymphoma, grade I, II, III; mantle cell lymphoma; Waldenstrom’s macroglobulinemia.
2. For NHL, all patients must have measurable disease.
3. Patients should have received no more than three prior regimens of conventional cytotoxic chemotherapy for at least four weeks prior to study enrollment (6 weeks for BCNU or mitomycin C). At least 7 days must have elapsed since steroids. A period of at least 3 months must have elapsed since the last administration of any monoclonal antibody.
4. Patients must be at least 18 years of age.
5. Patients must have adequate bone marrow, cardiac, kidney, and liver function.

This trial will evaluate response rate when bryostatin 1 is given in combination with vincristine in patients with low and intermediate grade non-Hodgkin’s lymphoma who have progressed or relapsed following an autologous bone marrow or stem cell transplant.  Patients will receive Bryostatin-1 in a single 24-hour intravenous infusion on Day 1.  This will be followed by a bolus IV injection of vincristine.  Patients will receive Bryostatin and vincristine every 2 weeks, for a minimum of one (1) cycle, for up to 6 months. A cycle of therapy will be considered 4 weeks (two bryostatin infusions, two vincristine infusions). For patients with responding or stable disease, or freedom from progression at 6 months, treatment may continue but bryostatin 1 and vincristine will be given every 3 weeks and a cycle of therapy will be considered 6 weeks.

1. Patients must have received a prior autologous bone marrow or peripheral blood stem cell rescue to be eligible for this trial (there is no specified time interval from transplant prior to enrollment on study. At least 4 weeks must have elapsed since prior large-field radiation therapy. Patients must have been off previous anti-cancer therapy for at least 4 weeks and recovered from all treatment related toxicity. Prior vincristine therapy is allowed.

2. Patients must have normal organ and marrow function.

3. Patients who have had a prior allogeneic transplant are not eligible.

4. Patients with known brain metastases or leptomeningeal involvement are excluded from this clinical trial.

This study will determine the toxicity and safety of PS-341 and Fludarabine in relapsed and refractory indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.  Patients will receive PS-341, IV on days 1, 4, 8 and 11 followed by a 10 day rest.  Fludarabine will be given one hour after PS-341, IV over 30 minutes on days 2 through 3 of each cycle (1 cycle = 3 weeks).  Patients may receive up to a maximum of 8 cycles.

1. Patients must have relapsed or refractory (progressive) indolent non-Hodgkin’s lymphoma.

2. Patients with non-Hodgkin’s lymphoma must have measurable disease.

3. Patients with relapsed indolent NHL (including CLL) will be enrolled in first, second, third relapse, or indolent NHL patients with progressive disease.

4. Prior fludarabine therapy is allowed; however patients should not have been previously treated with PS-341.

5. Patients who are candidates for potentially curative transplant therapies should not be entered on this study.

6. Patients must have normal bone marrow, hepatic and renal function.

This study will compare disease-free survival in patients with diffuse large cell lymphoma who have relapsed after achieving complete response or have failed to achieve initial complete response undergoing stem cell transplant with or without Rituximab.  Patients will be stratified to one of 2 treatment arms.  Patients in Arm A will receive Rituximab prior to stem cell removal and post stem cell reinfusion.  Patients in Arm B will not receive Rituximab. 

1. Patients must not be newly diagnosed.

2. Patients may have received a maximum of 3 prior regimens (using chemotherapy, radiation therapy, and immunotherapy).

3. Patients must not have had any prior Rituximab antibody therapy within the last 3 months.

4. Patients may not have received radioimmunotherapy.

5. Patients must have adequate bone marrow, hepatic and renal function.

6. Patients must have adequate cardiac and pulmonary function.